Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Research offers new hope for antibiotic resistance
Scientists say their findings could reverse the rising tide of antibiotic resistance.
Findings could ‘turn back the rising tide' of AMR

What makes some bacteria resistant to the most commonly prescribed antibiotics, and how this can be reversed, has been identified by scientists.

In a study, a team of researchers defined the relative importance of two mechanisms associated with β-lactams - a commonly prescribed group of antibiotics that includes penicillins, cephalosporins and carbapenems.

They found that, in one mechanism, bacteria restrict the entry of antibiotics into the cell. In the other, bacteria produce an enzyme, which destroys any antibiotic that gets into the cell. The latter was identified as the as the more important of the two mechanisms.

Scientists say their findings suggest that if chemicals could be developed to inhibit β-lactamase enzymes, a significant proportion of antibiotic resistance could be successfully reversed.

Building on these findings, a team from the University of Bristol studied the effectiveness of two types of β-lactamase enzyme inhibitor in a bacterium known to be highly resistant to common antibiotics.

They found both inhibitors failed consistently to protect the β-lactam antibiotic (ceftazidime) from attack by the β-lactamase enzyme. But when coupled with a different β-lactam antibiotic (aztreonam), the inhibitors worked very well - killing some of the most resistant bacteria the clinic had ever seen.

“Our bacteriology research has further demonstrated that β-lactamases are the real “Achilles heel” of antibiotic resistance in bacteria that kill thousands of people in the UK every year,” commented senior author Dr Matthew Alison from the University of Bristol.

“This is an exciting time for researchers studying β-lactamase inhibitors. At the risk of sounding like King Canute, it is the first time for a decade that there is some genuine positivity about our ability to turn back the rising tide of β-lactam antibiotic resistance.”

Become a member or log in to add this story to your CPD history

Building Great Workplaces webinars return

News Story 1
 BVA has announced a new series of its Building Great Workplaces lunchtime webinars.

Launching from 16 July, the sessions will explore patient safety, motivation, client communication and more.

Its first webinar, exploring neurodiversity in the workplace, will take place at 1pm on Thursday, 16 July. It will feature guest speakers from The Vet Project, a group which supports neurodiversity in veterinary environments.

The following three webinars take place in September, October and November.

Booking is open on the BVA website 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.